Derek Trezise

BBI Solutions OEM Ltd. develops and manufactures raw materials and finished test platforms for the in-vitro diagnostics market. It offers gold reagents, antibodies, antigens, biobank, cell culture, reagents, and enzymes. The firm services include lateral flow assay development, lateral flow test manufacture, and case studies. The company was founded in John Chandler in 1986 and is headquartered in Cardiff, the United Kingdom.

BBI Diagnostics Group Ltd. develops and manufactures raw materials and finished test platforms for the in-vitro diagnostics market. The firm’s products include cell culture reagents, conjugates, depleted serum, disease state plasma, enzymes, finished kits, gold nanoparticles, monoclonal antibodies, normal serums, patient samples, polyclonal antibodies, recombinant antibodies, silver nanoparticles, biothreat and explosives antibodies. It’s services include custom conjugation, lateral flow assay development, 3DNA pushing assay sensitivity to the limit, test optimisation, atomo rapid platform and the novarum reader. The company was founded by John Chandler in 1986 and is headquartered in Cardiff, the United Kingdom.

Axol Bioscience Ltd. is a biotech company that develops and produces induced pluripotent stem cell-derived clinically relevant cells for use in biomedical research and discovery. Its products include human neural progenitor cells, young frozen human cerebral cortical neurons, plated human cerebral cortical neurons, Alzheimer's disease human neural progenitor cells, reagents, and lipid-based transfection reagents. The firm's products are used in the testing of new drug compounds, as well as in the development of therapies for various diseases, such as Alzheimer’s. The company was founded by Yichen Shi and Jonathan Simon Milne and is headquartered in Cambridge, the United Kingdom.

Roslin Cell Therapies Ltd. is a leading contract development and manufacturing services organization focused on advanced cell and gene therapies. The company was established in 2006 and is based in Edinburgh, UK. and has subsidiaries in the United States. Roslin Cell Therapies has a remarkable heritage in the field, having been among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR edited stem cell-based therapy for a major disease to marketing authorization. The British company provides innovative process and analytical development, CGMP clinical and commercial manufacturing for a range of cell types, and CGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, Roslin Cell Therapies enables partners to efficiently progress from development to commercialization and deliver life-saving cell and gene therapies worldwide. Peter Alistair Coleman has been the CEO of the company since 2022.